GenSight Biologics Announces the Filing of its 2019 Universal Registration Document
Paris, France, April 8, 2020, 8.00 pm CET – GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2019 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.20-0271.
The universal registration document notably includes:
- the 2019 annual financial report;
- the management report;
- the report on corporate governance; and
- the description of the share buyback program.